Evidence map›Paper›PMID 24135862›Full record

ArticleNeurogenetics2014

SLC20A2 and THAP1 deletion in familial basal ganglia calcification with dystonia.

Matt Baker, Audrey J Strongosky, Monica Y Sanchez-Contreras, Shan Yang, Will Ferguson, Donald B Calne, Susan Calne, A Jon Stoessl, Judith E Allanson, Daniel F Broderick and 5 more

Abstract readCase Reports
In one paragraph

Article in Neurogenetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. The Importance of Neuropathology in a Complex Movement Disorder with Primary Familial Brain Calcification.Movement disorders : official journal of the Movement Disorder Society · 2026
    Article
  3. Article
  4. Deletion of the THAP1 Gene Is Responsible for Typical DYT-THAP1.Movement disorders clinical practice · 2025
    Article
  5. Article
  6. The Genetics of Primary Familial Brain Calcification: A Literature Review.International journal of molecular sciences · 2023
    Review
  7. Brain Calcifications: Genetic, Molecular, and Clinical Aspects.International journal of molecular sciences · 2023
    Review
  8. Article
  9. Article
  10. The importance of genetic testing for dystonia patients and translational research.Journal of neural transmission (Vienna, Austria : 1996) · 2021
    Review
  11. Isolated dystonia: clinical and genetic updates.Journal of neural transmission (Vienna, Austria : 1996) · 2021
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 3 countries.

Matt BakerDepartment of Neuroscience, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.
Audrey J Strongosky
Monica Y Sanchez-Contreras
Shan Yang
Will Ferguson
Donald B Calne
Susan Calne
A Jon Stoessl
Judith E Allanson
Daniel F Broderick
Michael L Hutton
Dennis W Dickson
Owen A Ross
Zbigniew K Wszolek
Rosa Rademakers
Mayo Clinic in Florida · USJacksonville College · USUniversity of British Columbia · CAComplete Genomics (United States) · USChildren's Hospital of Eastern Ontario · CAEli Lilly (United States) · US

Funding

Neuropathology CoreP50NS072187 · NINDS · MAYO CLINIC JACKSONVILLE · PI DICKSON, DENNIS WILLIAM · 2010 to 2017
$8.7M
NINDS NIH HHS P50 NS072187NINDS NIH HHS P50NS072187
6 · The paper itself

Abstract

Idiopathic basal ganglia calcification (IBGC) is characterized by bilateral calcification of the basal ganglia associated with a spectrum of neuropsychiatric and motor syndromes. In this study, we set out to determine the frequency of the recently identified IBGC gene SLC20A2 in 27 IBGC cases from the Mayo Clinic Florida Brain Bank using both Sanger sequencing and TaqMan copy number analysis to cover the complete spectrum of possible mutations. We identified SLC20A2 pathogenic mutations in two of the 27 cases of IBGC (7 %). Sequencing analysis identified a p.S113* nonsense mutation in SLC20A2 in one case. TaqMan copy number analysis of SLC20A2 further revealed a genomic deletion in a second case, which was part of a large previously reported Canadian IBGC family with dystonia. Subsequent whole-genome sequencing in this family revealed a 563,256-bp genomic deletion with precise breakpoints on chromosome 8 affecting multiple genes including SLC20A2 and the known dystonia-related gene THAP1. The deletion co-segregated with disease in all family members. The deletion of THAP1 in addition to SLC20A2 in the Canadian IBGC family may contribute to the severe and early onset dystonia in this family. The identification of an SLC20A2 genomic deletion in a familial form of IBGC demonstrates that reduced SLC20A2 in the absence of mutant protein is sufficient to cause neurodegeneration and that previously reported SLC20A2 mutation frequencies may be underestimated.

Indexed as

Gene DeletionAgedAged, 80 and overApoptosis Regulatory ProteinsBasal GangliaBrain DiseasesCalcinosisCanadaChromosome DeletionCodon, NonsenseDNA-Binding ProteinsDystoniaExomeFamily HealthFemaleGenomeApoptosis Regulatory ProteinsCodon, NonsenseDNA-Binding ProteinsNuclear ProteinsSLC20A2 protein, humanSodium-Phosphate Cotransporter Proteins, Type IIITHAP1 protein, human

Identifiers

PMID24135862
PMCPMC3969760
OpenAlexW1996770886

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.